On July 22nd, the sub-lists to Top 100 Chinese Pharmaceutical Enterprises of 2009 - The Ranking of Chinese Listed Pharmaceutical Enterprises, were released by the Southern Medical Economic Institute (hereafter referred to as “South Institute”) of State Food and Drug Administration (SFDA) in Guangzhou. Among the sub-lists, Fosun Pharma was awarded as the Most Profitable A-Share Pharmaceutical Listed Enterprise of 2009, the first on the Ranking (Top 20) of the Most Competitive A-Share Listed Chemicals Enterprises, the second on the Ranking (Top 50) of Most Competitive A-Share Listed Pharmaceutical Enterprises, which completely and greatly demonstrate the leading position and influence of Fosun Pharma in the pharmaceutical industry.

This is an original ranking created by the Southern Pharmaceutical Economic Institute of SFDA while it is also the first research report on account of the core competitiveness of listed pharmaceutical enterprises.

It is reported by South Institute that the Ranking was evaluated on the basis of the listed enterprises’ profitability, which has attracted great attention. According to South Institute, there are three indicators used to evaluate if an enterprise has the “profitability”, that are net profit, earnings per share and the currency ratio in total assets. Refer to net profit, thanks to Sinopharma having listed in Hong Kong last year, Fosun Pharma, with the net profit of RMB 2.56 billion, lists on the top. The second one is Shanghai Pharma with the net profit of RMB 1.68 billion.

South Institute and the experts group of the Ranking have created the four dictators to evaluate the most competitive listed pharmaceutical enterprises, i.e., scale, efficiency, growth and innovation, so as to comprehensively analyze and evaluate all listed enterprises in pharmaceutical industry and then elect the Top 50 Most Competitive Enterprise on the above basis.